PBPatrick Bruneval

Patrick Bruneval

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Patrick Bruneval has a total of 741 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Histopathologic patterns of iatrogenic arterial wall injury in thrombosed free-flap microanastomoses

    by Martin Lhuaire, Patrick Bruneval, Aïna Venkatasamy, Gwennhael Autret, Pierre Sohier, Geoffroy Noel, Vincent Hunsinger, Ignacio Garrido, Mohamed Derder, Peter Abrahams, et al.

  • Author Correction: Physiology and immunology of a pig-to-human decedent kidney xenotransplant

    by Robert A. Montgomery, Jeffrey M. Stern, Farshid Fathi, Nathan Suek, Jacqueline I. Kim, Karen Khalil, Benjamin Vermette, Vasishta S. Tatapudi, Aprajita Mattoo, Edward Y. Skolnik, et al.

  • Open Access

    Pathologic Evaluation of Pig Kidney and Heart Xenografts: 2024 Recommendations from the Banff Xenotransplantation Pathology Working Group

    by Ivy A. Rosales, Alton Brad Farris, Valentin Goutaudier, Aurelie Sannier, Huma Fatima, Claire Trivin-Avillach, Serena Bagnasco, Fiorella Calabrese, Marian C. Clahsen van Groningen, Shana M. Coley, et al.


  • Open Access

    NK cells promote cardiac cell death and regulate myelopoiesis in myocardial infarction

    by Raphael Cohen, Vincent Duval, Rida Al-Rifai, Sidrah Maryam, Icia Santos-Zas, Rayan Braik, Marc Diedisheim, Charlène Jouve, Simon Nicoletti, Sara Thietart, et al.

    Ischemic heart failure remains a major clinical challenge, underscoring the need to better understand post-infarction immune mechanisms and identify new therapeutic targets. Both innate and adaptive immunity contribute to adverse cardiac remodeling following myocardial infarction (MI), yet the role of cytotoxic cells such as natural killer (NK) cells remains poorly defined. Here, we show that after acute MI in mice, NK cells are recruited to the ischemic myocardium in a CCR2-dependent manner and become activated. Activated NK cells locally release granzyme B, promoting cardiomyocyte apoptosis, adverse ventricular remodeling, and impaired cardiac function. Genetic deletion or pharmacological depletion of NK cells reduces cardiomyocyte death, attenuates inflammation, limits myocardial injury, and improves cardiac function. In contrast, NK cell activation using an anti-NKG2A monoclonal antibody exacerbates ischemic heart failure. We further demonstrate that NK cells regulate bone marrow myelopoiesis through local GM-CSF production. Finally, we identify a distinct NK cellular and transcriptomic signature in human ischemic heart tissue at early stages. Together, these findings reveal a detrimental role for NK cells following acute MI and highlight NK cells as potential therapeutic targets to limit adverse cardiac remodeling.


  • Open Access

    Publisher Correction: Physiology and immunology of a pig-to-human decedent kidney xenotransplant

    by Robert A. Montgomery, Jeffrey M. Stern, Farshid Fathi, Nathan Suek, Jacqueline I. Kim, Karen Khalil, Benjamin Vermette, Vasishta S. Tatapudi, Aprajita Mattoo, Edward Y. Skolnik, et al.

  • Top Cited Papers

    Physiology and immunology of a pig-to-human decedent kidney xenotransplant

    by Robert A. Montgomery, Jeffrey M. Stern, Farshid Fathi, Nathan Suek, Jacqueline I. Kim, Karen Khalil, Benjamin Vermette, Vasishta S. Tatapudi, Aprajita Mattoo, Edward Y. Skolnik, et al.

    Xenotransplantation of genetically-modified pig kidneys offers a solution to the scarcity of organs for end-stage renal disease patients.1 We performed a 61-day alpha-Gal knock-out pig kidney and thymic autograft transplant into a nephrectomized brain-dead human using clinically approved immunosuppression, without CD40 blockade or additional genetic modification. Hemodynamic and electrolyte stability and dialysis independence were achieved. Post-operative day (POD) 10 biopsies revealed glomerular IgM and IgA deposition, activation of early complement components and mesangiolysis with stable renal function without proteinuria, a phenotype not seen in allotransplantation. On POD 33, an abrupt increase in serum creatinine was associated with antibody-mediated rejection and increased donor-specific IgG. Plasma exchange, C3/C3b inhibition and rabbit anti-thymocyte globulin (rATG), completely reversed xenograft rejection. Pre-existing donor-reactive T cell clones expanded progressively in the circulation post-transplant, acquired an effector transcriptional profile and were detected in the POD 33 rejecting xenograft prior to rATG treatment. This study provides the first long-term physiologic, immunologic, and infectious disease monitoring of a pig-to-human kidney xenotransplant and indicates that pre-existing xenoreactive T cells and induced antibodies to unknown epitope(s) present a major challenge, despite significant immunosuppression. It also demonstrates that a minimally gene-edited pig kidney can support long-term life-sustaining physiologic functions in a human.


  • Top Cited Papers
    Open Access

    Pathology-oriented multiplexing enables integrative disease mapping

    by Malte Kuehl, Yusuke Okabayashi, Milagros N. Wong, Lukas Gernhold, Gabriele Gut, Nico Kaiser, Maria Schwerk, Stefanie K. Gräfe, Frank Y. Ma, Jovan Tanevski, et al.

    The expression and location of proteins in tissues represent key determinants of health and disease. Although recent advances in multiplexed imaging have expanded the number of spatially accessible proteins1–3, the integration of biological layers (that is, cell structure, subcellular domains and signalling activity) remains challenging. This is due to limitations in the compositions of antibody panels and image resolution, which together restrict the scope of image analysis. Here we present pathology-oriented multiplexing (PathoPlex), a scalable, quality-controlled and interpretable framework. It combines highly multiplexed imaging at subcellular resolution with a software package to extract and interpret protein co-expression patterns (clusters) across biological layers. PathoPlex was optimized to map more than 140 commercial antibodies at 80 nm per pixel across 95 iterative imaging cycles and provides pragmatic solutions to enable the simultaneous processing of at least 40 archival biopsy specimens. In a proof-of-concept experiment, we identified epithelial JUN activity as a key switch in immune-mediated kidney disease, thereby demonstrating that clusters can capture relevant pathological features. PathoPlex was then used to analyse human diabetic kidney disease. The framework linked patient-level clusters to organ disfunction and identified disease traits with therapeutic potential (that is, calcium-mediated tubular stress). Finally, PathoPlex was used to reveal renal stress-related clusters in individuals with type 2 diabetes without histological kidney disease. Moreover, tissue-based readouts were generated to assess responses to inhibitors of the glucose cotransporter SGLT2. In summary, PathoPlex paves the way towards democratizing multiplexed imaging and establishing integrative image analysis tools in complex tissues to support the development of next-generation pathology atlases.


  • Immune checkpoint inhibitors–induced large vessel vasculitis: clinical characteristics and management from a European multicentre study

    by Adrien Cottu, Laure Delaval, Alexandra Forestier, Alessandro Tomelleri, Corrado Campochiaro, Milena Bond, Jérémie Dion, Aline Gury, Xavier Savary, Robin Dhote, et al.

    Objective: Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment but frequently cause immune-related adverse events (IrAEs). ICI-induced large vessel vasculitis (LVV) is a rare IrAE, with limited available data. We aimed to describe and compare clinical characteristics and evolution of ICI-induced LVV to primary LVV. Methods: This retrospective, multicentre European study included adult patients who developed LVV after ICI therapy between March 2018 and August 2024. Patients were compared with matched controls with primary LVV. LVV was defined histologically and/or morphologically. Results: Twenty-seven patients were included [median (interquartile range) age 68 (61–74) years]. Five (19%) had a history of polymyalgia rheumatica or GCA. Median time from ICIs initiation to LVV diagnosis was 3 (2–17) months. Eight patients (30%) received ipilimumab–nivolumab combination therapy, all of whom developed LVV within 6 months. Most clinical features were similar to matched controls, however PET scan diagnosis and large-vessel involvement were more common in ICI-induced LVV. Visual loss occurred in 4 (15%) patients. Management included discontinuation of ICIs in 19 (70%) patients and administration of glucocorticoids. After a median follow-up of 12 (5–20) months, 20 (74%) achieved sustained remission. Relapse or treatment failure of LVV occurred in 3/9 (33%) patients who continued ICIs and 4/18 (22%) who discontinued them. By last follow-up, 9 (33%) patients had died, mainly from cancer (n = 8). Conclusion: ICI-induced LVV is a rare, early-onset IrAE. Although continuation of ICIs may affect LVV outcomes, cancer progression remains the primary cause of mortality. Prospective studies are warranted to better balance therapeutic approaches.


  • Open Access

    Report of the 2022 Banff Heart Concurrent: Focus on non-human leukocyte antigen antibodies in rejection and the pathology of “mixed” rejection

    by Marny Fedrigo, Gerald J. Berry, Guillaume Coutance, Elaine F. Reed, Chieh-Yu Lin, Alessia Giarraputo, Evan Kransdorf, Olivier Thaunat, Martin Goddard, Annalisa Angelini, et al.


  • Validation of the clinical utility of microRNA as noninvasive biomarkers of cardiac allograft rejection: A prospective longitudinal multicenter study

    by Guillaume Coutance, Maud Racapé, Guillaume Baudry, Lucien Lécuyer, François Roubille, Katrien Blanchart, Eric Epailly, Emmanuelle Vermes, Sabine Pattier, Aude Boignard, et al.